At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 92 enrolled
Drug / intervention
Testosterone enanthate +1 moredrug
Likely dose
Testosterone enanthate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimizing Protein Intake in Older Americans With Mobility Limitations
In Brief
A Phase 3 clinical trial evaluating Testosterone enanthate for Mobility Limitation. Completed, enrolled 92 participants across 1 site.
Detailed Summary
This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of dietary protein intake and testosterone separately and together.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMobility Limitation
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartMay 2011
Primary CompletionJan 2017
TodayJul 2026
First PostedJan 12, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 19, 2017
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 15.5 years ago
Interventions
Testosterone enanthatedrug
Testosterone enanthate 100 mg intramuscularly weekly
Testosterone enanthatedrug
Testosterone enanthate 100 mg intramuscularly weekly